Takeda's zasocitinib proves top-notch for difficult-to-treat psoriasis in Phase 3 update

Takeda's oral TYK2 inhibitor zasocitinib has demonstrated "top-notch" efficacy in difficult-to-treat psoriasis lesions, including scalp, palms, and soles, in updated Phase 3 data from its Latitude PsO 3001 and 3002 trials.

In these global, double-blind, placebo- and active comparator–controlled studies, more than half of patients on zasocitinib achieved clear or almost clear skin (PASI 90) at week 16, with about 30% reaching complete clearance (PASI 100), significantly outperforming both placebo and apremilast (Otezla).

Zasocitinib showed rapid onset of action, with PASI 75 response significantly higher than placebo as early as week 4, and responses continued to improve through week 24, with over 90% of responders maintaining their benefit through week 60.

On hard-to-treat scalp psoriasis, 77% and 74% of patients achieved clear or almost clear scalp at week 16 with zasocitinib versus 7% and 13% on placebo and 42% and 30% on apremilast; similar superiority was seen in palm and sole psoriasis, with nearly 70% of zasocitinib recipients achieving clear or almost clear skin in these areas compared with 22% and 10% on placebo and 44% and 43% on apremilast.

The safety profile was generally favorable and consistent with prior studies, with the most common adverse events being upper respiratory tract infection, nasopharyngitis, and acne; no new safety signals were identified.

Takeda has completed two pivotal Phase 3 trials in moderate‑to‑severe plaque psoriasis and is preparing a New Drug Application for FDA and other regulatory agencies, positioning zasocitinib as a leading once‑daily oral TYK2 inhibitor for immune‑mediated inflammatory diseases.